<DOC>
	<DOCNO>NCT00023920</DOCNO>
	<brief_summary>This phase II trial see combine bevacizumab idarubicin cytarabine work well treat patient blast phase chronic myelogenous leukemia . Monoclonal antibody , bevacizumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill deliver cancer-killing substance . Drugs use chemotherapy , idarubicin cytarabine , work different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may effective treatment blast phase chronic myelogenous leukemia</brief_summary>
	<brief_title>Bevacizumab , Idarubicin , Cytarabine Treating Patients With Blast Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine anti-leukemic activity bevacizumab , idarubicin , cytarabine patient blastic phase chronic myelogenous leukemia . II . Determine toxicity profile regimen patient . III . Determine effect bevacizumab angiogenesis patient . OUTLINE : Patients receive bevacizumab IV 90 minute day -13 . Patients receive bevacizumab IV 90 minute idarubicin IV day 1 15 cytarabine subcutaneously ( SC ) daily begin day 1 . Treatment repeat every 4 week maximum 3 course . Patients respond disease receive maintenance therapy comprise bevacizumab IV 90 minute day 1 15 , idarubicin IV day 1 , cytarabine SC daily begin day 1 . Treatment repeat every 4 week 2 year absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis Philadelphia chromosomepositive blastic phase chronic myelogenous leukemia ( CML ) , define 1 following : At least 30 % blast peripheral blood and/or bone marrow Presence extramedullary disease Performance status Zubrod 02 At least 8 week No prior coagulopathies Bilirubin great 1.5 mg/dL INR le 2 PTT great 60 second Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No nephrotic syndrome No uncontrolled hypertension No New York Heart Association class IIIV heart disease No prior thrombotic event LVEF â‰¥ 50 % Not pregnant nursing Fertile patient must use effective contraception No 2 prior chemotherapy regimen ( 1 regimen contain cytarabine ) CML blast crisis Prior hydroxyurea allow Prior imatinib mesylate allow At least 10 day since prior anticoagulant No concurrent anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>